News
1don MSN
U.S. drugmaker Bristol Myers Squibb announced on Monday a $1.5 billion upfront payment to partner with Germany's BioNTech , ...
Germany’s Merck KGaA (MRK: DE) today announced the presentation of detailed positive results from Part 1 of the global Phase ...
A request to zone newly annexed land along Kansas Highway 10 could pave the way for future commercial development in De Soto.
Merck's KEYTRUDA Combo Cuts Risk By 35% In First-Line PD-L1+ Metastatic TNBC, Phase 3 Study Confirms
(RTTNews) - Merck & Co Inc. (MRK) announced that KEYTRUDA (pembrolizumab) plus Trodelvy (sacituzumab govitecan-hziy) reduced the risk of disease progression or death by 35% compared to KEYTRUDA plus c ...
[Triple-negative breast cancer (TNBC) - closeup view 3d illustration] Nemes Laszlo/iStock via Getty Images Gilead Sciences (NASDAQ:GILD [https://seekingalpha.com/symbol/GILD]) announced Saturday that ...
This week's dividend activity included increased payouts from BMO Financial (BMO) and Royal Bank of Canada (RY) as well as ...
Incyte's stock valuation is on the higher side given looming patent expiries for Jakafi and Opzelura, and uncertain pipeline ...
Jacobs Solutions is positioned for growth. Read more about the company's robust backlog and strong demand across water, ...
US stocks closed higher on Monday (June 2), the first trading session of June, as markets shrugged off mounting global trade ...
Several companies are advancing treatments for anal cancer, including Merck (KEYTRUDA), BioMimetix (BMX-001), Novartis (KFA115), and Bicara Therapeutics (BCA101), among others. As immunotherapy ...
1d
MedPage Today on MSNADC-Pertuzumab Promising as New Standard in HER2-Positive Metastatic Breast CancerAs such, "the combination of T-DXd and pertuzumab may represent a new first-line standard of care for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results